Micromet to Host Annual Research & Development Day on February 10, 2010
February 04 2010 - 7:01AM
PR Newswire (US)
BETHESDA, Md., Feb. 4 /PRNewswire-FirstCall/ -- Micromet, Inc.
(NASDAQ: MITI) today announced that it will host a Research &
Development Day for the investment community on Wednesday, February
10, 2010 from 8:00 AM - 11:00 AM ET at the Yale Club in New York
City. Members of the Company's leadership team will outline
near-term development plans for the Company's lead product
candidate blinatumomab (MT103) and will provide an update on the
Company's earlier stage BiTEĀ® antibodies. Interested parties may
access a live audio webcast of the presentation via the homepage of
the Micromet website, http://www.micromet-inc.com/ or by dialing
866-700-7477 (U.S.) or 617-213-8840 (International), passcode:
23649136. About Micromet, Inc. Micromet, Inc. is a
biopharmaceutical company focused on the discovery, development and
commercialization of antibody-based therapies for the treatment of
cancer. Its product development pipeline includes novel antibodies
generated with its proprietary BiTEĀ® technology, as well as
conventional monoclonal antibodies. Two of Micromet's BiTE
antibodies and three of its conventional antibodies are currently
in clinical trials. Micromet has collaborations with a number of
leading pharmaceutical and biotechnology companies, including
sanofi-aventis, Bayer Schering Pharma, Merck Serono, MedImmune and
Nycomed. Additional information can be found at
http://www.micromet-inc.com/. DATASOURCE: Micromet, Inc. CONTACT:
Jennifer Neiman, Director, Corporate Communications, Micromet,
Inc., +1-240-235-0246, Web Site: http://www.micromet-inc.com/
Copyright